SYDNEY, June 8, 2026, 08:04 (AEST)
- Telix ended Friday at A$13.31, rising 3.26%. Google Finance listed the price as of 4:10 p.m. in Sydney.
- The ASX cash market shuts Monday for the King’s Birthday, with no settlement that day.
Telix Pharmaceuticals heads into the shortened Australian trading week with new momentum. Shares climbed on Friday, moving against a weaker market. Investors are again watching the company’s cancer-imaging and therapy pipeline.
No Monday trade means the next test for the stock comes after the holiday. Investors will be looking at Friday’s rebound and weighing it against a global risk-off mood that followed a big drop in U.S. stocks. Friday’s jobs data revived interest rate fears.
Telix finished Friday at A$13.31, rising 42 cents. According to Trading Economics, the stock gained 12.49% over the last four weeks but remained 47.93% lower for the past year. The S&P/ASX 200 slipped 0.70% on June 5, Trading Economics said.
Telix buyers aren’t pointing to a single factor. The focus is on a string of company updates last week, like Telix’s June 2 MOU with United Imaging Healthcare North America. That deal aims to look at a U.S. research tie-up using Telix imaging kits with United Imaging’s scanners, software and AI products. “Close alignment” is needed between scanners, software, and radiopharmaceuticals, Telix Precision Medicine CEO Kevin Richardson said. Telix Pharmaceuticals Limited
Telix presented Part 1 data from its ProstACT Global Phase 3 trial for prostate cancer at the American Society of Clinical Oncology meeting in Chicago. The company reported TLX591-Tx was tolerated and did not show any new safety issues in metastatic castration-resistant prostate cancer, where the disease spreads and continues despite hormone-lowering therapy. Pedro C. Barata, a study investigator, said the data “support further evaluation” during the randomized phase. Telix Pharmaceuticals
Telix keeps leaning on its commercial base. First-quarter unaudited group revenue came in at US$230 million, an 11% rise from the previous quarter. The company kept its 2026 revenue guidance at US$950 million to US$970 million. CEO Christian Behrenbruch said there was faster growth in the precision medicine segment, including prostate-cancer imaging drugs Illuccix and Gozellix.
Lantheus is pushing ahead in the prostate-cancer imaging space. The U.S. radiopharma company grabbed FDA approval in March for Pylarify TruVu, which is a new version of its PSMA imaging agent. PSMA PET scans rely on a radioactive tracer to track the return or spread of prostate cancer. Truist’s Richard Newitter called the FDA green light an “important catalyst,” according to Reuters. Reuters
Novartis is another big name investors track. The company said last week its actinium-based radiopharmaceutical showed anti-tumour activity in advanced prostate cancer, even in patients treated before with Pluvicto. Novartis will take the drug into two late-stage studies, Reuters reported. The move points to how crowded and well-funded this space now is.
Clinical promise often doesn’t translate to approvals, strong labels or good sales. Telix ran into this in August 2025 when the U.S. FDA asked for more data on its application for a kidney-cancer imaging drug, citing issues in manufacturing and supply chain. Shares dropped sharply after that news. Jun Bei Liu, portfolio manager at Ten Cap, told Reuters at the time that the problem could be “far more significant” if it was about the manufacturing process. Reuters
Looking to the week, markets want to see if Friday’s buying held any real weight or if it just came from thin trading before the holiday. When trading starts Tuesday, it’ll be clear if investors are still willing to back Telix’s pipeline, despite the ongoing regulatory overhang, production challenges and deep-pocketed competitors.
